In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management

In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management

Abstract Long-term proteasome inhibitor (PI) treatment can improve multiple myeloma (MM) outcomes, but this can be difficult to achieve in clinical practice due to toxicity, comorbidities, and the burden of repeated parenteral administration. US MM-6 (NCT03173092) enrolled transplant-ineligible pati...

Full description

Bibliographic Details
Main Authors: Robert M. Rifkin, Saulius K. Girnius, Stephen J. Noga, Ruemu E. Birhiray, Suman Kambhampati, Sudhir Manda, Roger M. Lyons, Habte A. Yimer, Dasha Cherepanov, Eric Lloyd, Presley Whidden, Joshua Richter
Format: Article
Language:English
Published: Nature Publishing Group 2023-09-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-023-00912-9

Internet

https://doi.org/10.1038/s41408-023-00912-9

Similar Items